Discontinued — last reported Q4 '17
Carnival Corporation Indefinite-Lived Research and Development Assets increased by 0.3% to $1.18B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 1.7%, from $1.16B to $1.18B. Over 5 years (FY 2020 to FY 2025), Indefinite-Lived Research and Development Assets shows relatively stable performance with a -0.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates active investment in future technology, while a decrease may signal project completion or impairment.
These are acquired in-process research and development (IPR&D) projects that have not yet reached technological feasibil...
Common in technology and pharmaceutical sectors following M&A activity.
indefinite_lived_rd_assets| Q1 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.19B | $1.18B | $1.16B | $1.15B | $1.15B | $1.15B | $1.16B | $1.16B | $1.16B | $1.16B | $1.16B | $1.17B | $1.16B | $1.16B | $1.18B | $1.18B | $1.18B | $1.18B |
| QoQ Change | — | -1.4% | -1.2% | -1.4% | +0.5% | +0.1% | +0.5% | +0.4% | +0.1% | -0.1% | +0.0% | +0.7% | -0.9% | -0.1% | +1.5% | +0.3% | -0.3% | +0.3% |
| YoY Change | — | — | -2.6% | — | -2.0% | — | -0.3% | +1.6% | +1.1% | +1.0% | +0.4% | +0.7% | -0.3% | -0.3% | +1.2% | +0.8% | +1.3% | +1.7% |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Europe Segment | $236.00M | $244.00M | $234.00M | $233.00M | $250.00M | $252.00M | $249.00M | $253.00M |
| North America And Australia | $927.00M | $927.00M | $927.00M | — | — | — | — | — |
| North America Segment | — | — | — | — | — | — | $927.00M | — |
| Total | $1.16B | $1.17B | $1.16B | $1.16B | $1.18B | $1.18B | $1.18B | $1.18B |